Skip to content

About Curtis Geier, PharmD BCCCP

Clinical Pharmacist, Emergency Medicine
Assistant Clinical Professor, UCSF
San Francisco General Hospital and Trauma Center
10 08, 2018

Replace dolutegravir (Tivicay) with raltegravir (Isentress) for post-exposure prophylaxis

2018-08-10T04:08:00+00:00

raltegravirPost-exposure prophylaxis (PEP) of patients who may have been exposed to HIV includes a combination HIV nucleoside analog reverse transcriptase inhibitor emtricitabine/tenofovir (Truvada) plus an integrase inhibitor. The CDC initially recommended the integrase inhibitor dolutegravir (Tivicay). However on May 18, 2018, the CDC placed an alert about the neural tube defect risk with dolutegravir.1 How does this change our ED practice?
(more…)

10 01, 2018

Prochlorperazine, Metoclopramide, and Diphenhydramine for Acute Migraine Headache

The 2016 American Headache Society (AHS) released recommendations on managing adults with acute migraine headaches.1 In the November 2017 EM:RAP LIN Sessions podcast episode that I recorded, I realized that I overgeneralized several statements about anti-dopaminergic agents and the use of concurrent diphenhydramine for akathisia risk reduction. So I wanted to clarify things and share a deeper-dive on the topic, thanks to the constructive feedback and help of headache guru Dr. David Vinson and EM pharmacists Dr. Curtis Geier, Dr. Bryan Hayes, and Dr. Zlatan Coralic. Below summarizes the nuanced thought processes in the anti-dopaminergic treatment of migraines.

(more…)